Volume 23, Number 5—May 2017
Antimicrobial Drug Resistance among Refugees from Syria, Jordan
Highlight and copy the desired format.
|EID||Abbara A, Al-Harbat N, Karah N, Abo-Yahya B, El-Amin W, Hatcher J, et al. Antimicrobial Drug Resistance among Refugees from Syria, Jordan. Emerg Infect Dis. 2017;23(5):885-886. https://dx.doi.org/10.3201/eid2305.170117|
|AMA||Abbara A, Al-Harbat N, Karah N, et al. Antimicrobial Drug Resistance among Refugees from Syria, Jordan. Emerging Infectious Diseases. 2017;23(5):885-886. doi:10.3201/eid2305.170117.|
|APA||Abbara, A., Al-Harbat, N., Karah, N., Abo-Yahya, B., El-Amin, W., Hatcher, J....Gabbar, O. (2017). Antimicrobial Drug Resistance among Refugees from Syria, Jordan. Emerging Infectious Diseases, 23(5), 885-886. https://dx.doi.org/10.3201/eid2305.170117.|
To the Editor: The Kassem et al. article regarding high rates of multidrug-resistant (MDR) bacteria colonizing Syrian children highlights the challenge of choosing empiric antimicrobial drugs to treat war-injured refugees from Syria (1). The findings mirror other reports (2–3) and our own experience in a charitable hospital in Amman, Jordan, which manages war-injured refugees from Syria. As part of a program of antimicrobial drug stewardship and infection prevention and control, empiric antimicrobial drug protocols were introduced. For antimicrobial drug–naive patients, the first-line choice for prophylaxis and treatment of skin and soft-tissue infections, including those involving open fractures, was a narrow-spectrum cephalosporin, as recommended by the Infectious Diseases Society of America guidelines (4); however, clinical failure was common.
We retrospectively reviewed the clinical microbiology data of 75 patients admitted in January 2015 with a history of suspected post-trauma infection. All these patients were first treated in field hospitals in Syria; 82.7% were male, and 33% were <16 years old. Twenty-four percent had multiple injuries, 20% had osteomyelitis, and 53% had metal prosthetic implants.
Thirty bacterial isolates were identified, mostly from deep wound swabs of 21 (28%) injured patients; 9/21 were infected with 2 isolates. Twenty-nine (97%) isolates were gram-negative bacteria: 10 Proteus spp., 10 Escherichia coli, 5 Pseudomonas spp., and 4 Klebsiella spp. Disk diffusion susceptibility testing showed that 20 (66%) isolates were MDR and 11 (36.7%) were carbapenem resistant.
The hospital laboratory did not have the capacity to perform further testing and confirmation of the resistant strains in line with international quality standards because they lacked suitable equipment and financial resources. Preventing further dissemination of MDR organisms among war-injured refugees from Syria at hosting healthcare facilities requires an effective surveillance system, investment in infection prevention and control, appropriate antimicrobial drug stewardship, and urgent laboratory capacity building inside Syria and in the refugee-host countries.
- Kassem DF, Hoffmann Y, Shahar N, Ocampo S, Salomon L, Zonis Z, et al. Multidrug-resistant pathogens in hospitalized Syrian children. Emerg Infect Dis. 2017;23:166–8.
- Reinheimer C, Kempf VAJ, Göttig S, Hogardt M, Wichelhaus TA, O’Rourke F, et al. Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June‒December 2015. Euro Surveill. 2016;21:30110.
- Teicher CL, Ronat JB, Fakhri RM, Basel M, Labar AS, Herard P, et al. Antimicrobial drug-resistant bacteria isolated from Syrian war-injured patients, August 2011-March 2013. Emerg Infect Dis. 2014;20:1949–51.
- Hospenthal DR, Murray CK, Andersen RC, Bell RB, Calhoun JH, Cancio LC, et al.; Infectious Diseases Society of America; Surgical Infection Society. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. J Trauma. 2011;71(Suppl 2):S210–34.
- Page created: April 17, 2017
- Page last updated: April 17, 2017
- Page last reviewed: April 17, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)